1. Home
  2. HURA vs DTSQ Comparison

HURA vs DTSQ Comparison

Compare HURA & DTSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • DTSQ
  • Stock Information
  • Founded
  • HURA 2009
  • DTSQ 2022
  • Country
  • HURA United States
  • DTSQ United States
  • Employees
  • HURA N/A
  • DTSQ N/A
  • Industry
  • HURA
  • DTSQ
  • Sector
  • HURA
  • DTSQ
  • Exchange
  • HURA Nasdaq
  • DTSQ NYSE
  • Market Cap
  • HURA 96.5M
  • DTSQ 90.9M
  • IPO Year
  • HURA N/A
  • DTSQ 2024
  • Fundamental
  • Price
  • HURA $3.48
  • DTSQ $10.24
  • Analyst Decision
  • HURA Strong Buy
  • DTSQ
  • Analyst Count
  • HURA 2
  • DTSQ 0
  • Target Price
  • HURA $12.00
  • DTSQ N/A
  • AVG Volume (30 Days)
  • HURA 272.1K
  • DTSQ 1.9K
  • Earning Date
  • HURA 05-15-2025
  • DTSQ 01-01-0001
  • Dividend Yield
  • HURA N/A
  • DTSQ N/A
  • EPS Growth
  • HURA N/A
  • DTSQ N/A
  • EPS
  • HURA N/A
  • DTSQ N/A
  • Revenue
  • HURA N/A
  • DTSQ N/A
  • Revenue This Year
  • HURA N/A
  • DTSQ N/A
  • Revenue Next Year
  • HURA $221.29
  • DTSQ N/A
  • P/E Ratio
  • HURA N/A
  • DTSQ $76.32
  • Revenue Growth
  • HURA N/A
  • DTSQ N/A
  • 52 Week Low
  • HURA $1.80
  • DTSQ $9.96
  • 52 Week High
  • HURA $14.60
  • DTSQ $10.37
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • DTSQ N/A
  • Support Level
  • HURA N/A
  • DTSQ N/A
  • Resistance Level
  • HURA N/A
  • DTSQ N/A
  • Average True Range (ATR)
  • HURA 0.00
  • DTSQ 0.00
  • MACD
  • HURA 0.00
  • DTSQ 0.00
  • Stochastic Oscillator
  • HURA 0.00
  • DTSQ 0.00

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About DTSQ DT CLOUD STAR ACQUISITION CORP

DT Cloud Star Acquisition Corp is a blank check company.

Share on Social Networks: